<p>脑机接口（BCI）技术在大脑电活动和数字设备之间建立了直接联系。这种连接可以在辅助、增强和修复人类认知功能方面带来广泛的好处。</p>
<p>预测显示，到 2030 年，全球 BCI 市场预计以每年 17.5% 的复合年增长率增长，达到 620 亿美元。新的使用案例的出现将推动该行业在未来几年取得进展。</p>
<p>脑机接口有许多用途。它们可以在生物技术、医学研究、心理健康甚至游戏等行业中发挥重要作用。</p>
<p>事实上，医疗技术公司在新冠疫情之后在华尔街上迅速增长。然而，许多领先股票难以保持势头。与此同时，生成式人工智能（AI）热潮吸引了各种规模的投资者的想象力。</p>
<p>然而，截至 2020 年人口普查，美国 65 岁及以上人口数量增至 5580 万。因此，该国日益老龄化的人口可能导致医疗技术的更广泛应用。投资者可能会看到脑机接口股票作为长期持有而加速增值。在这种情况下，关键的股市考虑包括这三家最佳脑机接口股票。</p>
<h2>Clearpoint Neuro Inc（CLPT）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Panuwach/Shutterstock</p>
<p>在生物技术领域，Clearpoint Neuro Inc（纳斯达克：CLPT）在细胞和基因疗法领域建立了强大的存在，专注于对大脑和脊柱的导航。</p>
<p>凭借超过 2 亿美元的市值，在生物制品和药物递送方面拥有 50 多个合作伙伴以及全球 75 多家神经外科中心，该公司有望在这个仍在兴起的行业中实现增长。</p>
<p>在过去 12 个月中，Clearpoint 并没有盈利。然而，这并没有影响投资者，他们仅在 7 月就将股价推高了 40% 以上。总体而言，CLPT 在过去一年中增长了 16.87%，但仍然低于 2012 年创下的历史最高市值近 95%。</p>
<p>这表明该公司有很大的增长空间，鉴于该公司在药物递送方面的积极动向以及新增服务的前景，我们可能会看到该股票在更长期的未来挑战恢复其昔日辉煌。</p>
<h2>Snap Inc（SNAP）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：BigTunaOnline / Shutterstock</p>
<p>前社交媒体巨头、现科技创新公司 Snap Inc（纽约证券交易所：SNAP）在考虑的脑机接口公司中确实是一个非传统的选择。但从增长前景来看，也许没有比它更好的选择了。</p>
<p>就业绩而言，Snap 在 2024 财年第二季度结束时距离其在 2021 年 9 月记录的疫情后市场高点下跌了 80%。然而，像摩根士丹利（纽约证券交易所：MS）这样的公司最近根据该公司广告表现的改善，将其股价预测从 12 美元上调至 15 美元。</p>
<p>然而，Snap 的长期可持续性取决于其在战略收购方面的动向。2022 年，这家科技公司收购了 NextMind，一家以其 BCI 控制器而闻名的法国初创公司，该控制器使用大脑信号在 PC 界面上移动图像。</p>
<p>作为虚拟现实（VR）和增强现实（AR）技术的关键参与者，脑机接口技术在游戏领域的实用性对于 SNAP 可能是一项开创性举措。</p>
<h2>英特格拉生命科学（IART）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：shutterstock.com/cono0430</p>
<p>在 BCI 技术领域多年来一直引起轰动的股票之一是英特格拉生命科学（纳斯达克：IART）。它最初于 1995 年上市，并于 2007 年推出了用于帕金森病治疗的脑图软件。</p>
<p>与许多以医疗为重点的股票一样，英特格拉生命科学在 2021 年产生的势头上难以持续发展。目前，它的股价比疫情后的高点低了 50% 以上。</p>
<p>尽管如此，医疗器械制造商市场上有许多积极的动向，2024 年第一季度，佛罗里达州退休系统州立董事会将其在 IART 的持股增加了 18.6%，将其在该公司的持股增加至 289.3 万美元。</p>
<p>英特格拉生命科学在脑机接口技术领域拥有悠久而丰富的历史，有望在生物技术领域以及许多其他行业中实现 BCI 工具的实施而跃居行业前沿。考虑到这一点，该股票对投资者来说可能是一个强有力的投机选择。</p>
<p>_在本文发布日期，Dmytro Spilka 没有持有（直接或间接）本文提到的证券任何头寸。本文中表达的观点属于作者本人，受 InvestorPlace.com 发布指南的约束。</p>
<p>_在本文发布日期，负责编辑没有持有（直接或间接）本文提到的证券任何头寸。</p>
<p>Dmytro 是一位居住在伦敦的金融和投资作家。他还是 Solvid、Pridicto 和 Coinprompter 的创始人。他的作品曾发表在纳斯达克、基普林格、FXStreet、企业家、VentureBeat 和 InvestmentWeek 等媒体上。</p>
<p>人工智能、生物技术、医疗保健、软件、技术、视频游戏</p>

英特格拉生命科学

<p>全球脑机接口（BCI）技术市场预计将以 17.5% 的复合年增长率增长，到 2030 年将达到 62 亿美元。这项技术在生物技术、医学研究、心理健康和游戏等行业有各种应用。在 BCI 领域，有三家有潜力的股票可供考虑，它们分别是 Clearpoint Neuro Inc（CLPT）、Snap Inc（SNAP）和英特格拉生命科学（IART）。这些公司在 BCI 领域显示出增长和创新的潜力</p>

<p>Brain-computer interface ( <strong>BCI</strong>) technology creates a direct link between the brain’s electrical activity and a digital device. This connection can bring a vast range of benefits in assisting, augmenting and repairing human cognitive functions.</p>
<div class="lb-trans"><p>脑机接口（BCI）技术在大脑电活动和数字设备之间建立了直接联系。这种连接可以在辅助、增强和修复人类认知功能方面带来广泛的好处。</p>
</div><p>Forecasts predict global BCI market growth rallying at a compound annual growth rate ( <strong>CAGR</strong>) of 17.5% to a value of $6.2 billion by 2030. The emergence of new use cases will drive the sector forward over the coming years.</p>
<div class="lb-trans"><p>预测显示，到 2030 年，全球 BCI 市场预计以每年 17.5% 的复合年增长率增长，达到 620 亿美元。新的使用案例的出现将推动该行业在未来几年取得进展。</p>
</div><p>Brain-computer interfaces have a number of purposes. They can be used to great effect in industries like biotechnology, medical research, mental wellness and even gaming.</p>
<div class="lb-trans"><p>脑机接口有许多用途。它们可以在生物技术、医学研究、心理健康甚至游戏等行业中发挥重要作用。</p>
</div><p>Indeed, medical technology firms grew at a significant pace on Wall Street in the wake of Covid-19. Yet, many leading stocks have struggled to maintain momentum. Simultaneously, the generative artificial intelligence ( <strong>AI</strong>) boom has captured the imagination of investors of all scales.</p>
<div class="lb-trans"><p>事实上，医疗技术公司在新冠疫情之后在华尔街上迅速增长。然而，许多领先股票难以保持势头。与此同时，生成式人工智能（AI）热潮吸引了各种规模的投资者的想象力。</p>
</div><p>However, the number of U.S. citizens aged 65 and above grew to 55.8 million, as of the 2020 census. Thus, the nation’s aging population is likely to lead to a more widespread adoption of medical technology. Investors could see brain-computer interface stocks accelerate in value as long-term holds. In this scenario, key stock market considerations include these three best brain-computer interface stocks.</p>
<div class="lb-trans"><p>然而，截至 2020 年人口普查，美国 65 岁及以上人口数量增至 5580 万。因此，该国日益老龄化的人口可能导致医疗技术的更广泛应用。投资者可能会看到脑机接口股票作为长期持有而加速增值。在这种情况下，关键的股市考虑包括这三家最佳脑机接口股票。</p>
</div><h2><strong>Clearpoint Neuro Inc (CLPT)</strong></h2>
<div class="lb-trans"><h2>Clearpoint Neuro Inc（CLPT）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Panuwach/Shutterstock</p>
<div class="lb-trans"><p>来源：Panuwach/Shutterstock</p>
</div><p>When it comes to biotechnology, <strong>Clearpoint Neuro Inc</strong> (NASDAQ:<strong>CLPT</strong>) has built a strong presence in the field of cell and gene therapy, focusing on navigation to the brain and spine.</p>
<div class="lb-trans"><p>在生物技术领域，Clearpoint Neuro Inc（纳斯达克：CLPT）在细胞和基因疗法领域建立了强大的存在，专注于对大脑和脊柱的导航。</p>
</div><p>With a market capitalization of over $200 million, a collective of more than 50 partners in biologics and drug delivery, and over 75 neurosurgery centers globally, the company is well-positioned to grow into an industry that’s still emerging.</p>
<div class="lb-trans"><p>凭借超过 2 亿美元的市值，在生物制品和药物递送方面拥有 50 多个合作伙伴以及全球 75 多家神经外科中心，该公司有望在这个仍在兴起的行业中实现增长。</p>
</div><p>Clearpoint hasn’t been profitable in the past 12 months. Yet this doesn’t appear to faze investors, who have pushed the stock more than 40% higher in July alone. Zooming out, CLPT has grown 16.87% in the last year, but still sits almost 95% below its all-time high market value back in 2012.</p>
<div class="lb-trans"><p>在过去 12 个月中，Clearpoint 并没有盈利。然而，这并没有影响投资者，他们仅在 7 月就将股价推高了 40% 以上。总体而言，CLPT 在过去一年中增长了 16.87%，但仍然低于 2012 年创下的历史最高市值近 95%。</p>
</div><p>This suggests the firm has plenty of room for growth, and judging by the firm’s positive movements in drug delivery and the prospect of new services added to the mix, we could see the stock mount a challenge to recover its former glories in the more long-term future.</p>
<div class="lb-trans"><p>这表明该公司有很大的增长空间，鉴于该公司在药物递送方面的积极动向以及新增服务的前景，我们可能会看到该股票在更长期的未来挑战恢复其昔日辉煌。</p>
</div><h2><strong>Snap Inc (SNAP)</strong></h2>
<div class="lb-trans"><h2>Snap Inc（SNAP）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: BigTunaOnline / Shutterstock</p>
<div class="lb-trans"><p>来源：BigTunaOnline / Shutterstock</p>
</div><p>Former social media giant and current tech innovator, <strong>Snap Inc</strong> (NYSE:<strong>SNAP</strong>) is certainly an unconventional brain-computer interface company to consider. But there may be no better option for portfolios in terms of growth prospects.</p>
<div class="lb-trans"><p>前社交媒体巨头、现科技创新公司 Snap Inc（纽约证券交易所：SNAP）在考虑的脑机接口公司中确实是一个非传统的选择。但从增长前景来看，也许没有比它更好的选择了。</p>
</div><p>In terms of performance, Snap ended Q2 of fiscal year 2024 80% adrift from its post-pandemic market high recorded in September 2021. However, the likes of <strong>Morgan Stanley</strong> (NYSE:<strong>MS</strong>) have recently upgraded their price predictions for the stock from $12 to $15 based on improving ad performance for the company.</p>
<div class="lb-trans"><p>就业绩而言，Snap 在 2024 财年第二季度结束时距离其在 2021 年 9 月记录的疫情后市场高点下跌了 80%。然而，像摩根士丹利（纽约证券交易所：MS）这样的公司最近根据该公司广告表现的改善，将其股价预测从 12 美元上调至 15 美元。</p>
</div><p>However, Snap’s long-term sustainability is driven by its movements in strategic acquisitions. In 2022, the tech firm acquired NextMind, a French startup that’s best known for its BCI controller, which uses brain signals to move images on a PC interface.</p>
<div class="lb-trans"><p>然而，Snap 的长期可持续性取决于其在战略收购方面的动向。2022 年，这家科技公司收购了 NextMind，一家以其 BCI 控制器而闻名的法国初创公司，该控制器使用大脑信号在 PC 界面上移动图像。</p>
</div><p>As a key player in virtual reality ( <strong>VR</strong>) and augmented reality ( <strong>AR</strong>) technology, the utility of brain-computer interface technology in the field of gaming could be a pioneering move for SNAP.</p>
<div class="lb-trans"><p>作为虚拟现实（VR）和增强现实（AR）技术的关键参与者，脑机接口技术在游戏领域的实用性对于 SNAP 可能是一项开创性举措。</p>
</div><h2><strong>Integra Lifesciences (IART)</strong></h2>
<div class="lb-trans"><h2>英特格拉生命科学（IART）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: shutterstock.com/cono0430</p>
<div class="lb-trans"><p>来源：shutterstock.com/cono0430</p>
</div><p>One example of a stock that’s been making waves in BCI technology for many years in <strong>Integra Lifesciences</strong>(NASDAQ:<strong>IART</strong>). It initially went public in 1995 and debuted brain mapping software as a treatment for Parkinson’s Disease in 2007.</p>
<div class="lb-trans"><p>在 BCI 技术领域多年来一直引起轰动的股票之一是英特格拉生命科学（纳斯达克：IART）。它最初于 1995 年上市，并于 2007 年推出了用于帕金森病治疗的脑图软件。</p>
</div><p>Like many medically-focused stocks, Integra Lifesciences has struggled to build on the momentum generated in 2021. Currently, it sits more than 50% below its post-pandemic highs.</p>
<div class="lb-trans"><p>与许多以医疗为重点的股票一样，英特格拉生命科学在 2021 年产生的势头上难以持续发展。目前，它的股价比疫情后的高点低了 50% 以上。</p>
</div><p>Despite this, there have been plenty of positive market movements for the medical device manufacturer, and in July IART announced that it plans to have a state-of-the-art facility operational in Braintree, Massachusetts by the first half of 2026.</p>
<div class="lb-trans"><p>尽管如此，医疗器械制造商市场上有许多积极的动向，2024 年第一季度，佛罗里达州退休系统州立董事会将其在 IART 的持股增加了 18.6%，将其在该公司的持股增加至 289.3 万美元。</p>
</div><p>The first quarter of 2024 has also seen the State Board of Administration of Florida Retirement System increase its stake by 18.6% in IART, increasing its holdings in the company to a value of $2,893,000.</p>
<div class="lb-trans"><p>英特格拉生命科学在脑机接口技术领域拥有悠久而丰富的历史，有望在生物技术领域以及许多其他行业中实现 BCI 工具的实施而跃居行业前沿。考虑到这一点，该股票对投资者来说可能是一个强有力的投机选择。</p>
</div><p>With a long and rich history in brain-computer interface technology, Integra Lifesciences has the potential to leap to the forefront of the industry’s emergence in the fields of biotech and the many other industries that could benefit from the implementation of BCI tools. With this in mind, the stock could be a strong speculative option for investors.</p>
<div class="lb-trans"><p>_在本文发布日期，Dmytro Spilka 没有持有（直接或间接）本文提到的证券任何头寸。本文中表达的观点属于作者本人，受 InvestorPlace.com 发布指南的约束。</p>
</div><p><em>On the date of publication, Dmytro Spilka did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p>_在本文发布日期，负责编辑没有持有（直接或间接）本文提到的证券任何头寸。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>Dmytro 是一位居住在伦敦的金融和投资作家。他还是 Solvid、Pridicto 和 Coinprompter 的创始人。他的作品曾发表在纳斯达克、基普林格、FXStreet、企业家、VentureBeat 和 InvestmentWeek 等媒体上。</p>
</div><p>Dmytro is a finance and investing writer based in London. He is also the founder of Solvid, Pridicto and Coinprompter. His work has been published in Nasdaq, Kiplinger, FXStreet, Entrepreneur, VentureBeat and InvestmentWeek.</p>
<div class="lb-trans"><p>人工智能、生物技术、医疗保健、软件、技术、视频游戏</p>
</div><p>Artificial Intelligence, Biotech, Healthcare, Software, Technology, Video Games</p>

现在值得购买的三只最佳脑机接口股票